HR Execs on the Move

LifeCell Corporation

www.lifecell.com

 
LifeCell Corporation develops, processes and markets biological soft tissue repair products made from human (allograft) and animal (xenograft) tissue.
  • Number of Employees: 0-25
  • Annual Revenue: $100-250 Million
  • www.lifecell.com
  • 1 Millennium Way
    Somerville, NJ USA 08876-3876
  • Phone: 908.947.1100

Executives

Name Title Contact Details
Patrick Leamy
Director, Research & Development Profile
Hui Xu
Senior Director & Science Fellow R&D Profile

Similar Companies

Chinese Community Health Plan

Chinese Community Health Plan is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Aspenbio Pharma Inc

Aspenbio Pharma Inc is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Castle Rock, CO. To find more information about Aspenbio Pharma Inc, please visit www.aspenbiopharma.com

Medafor

Medafor is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Stille Surgical

Stille Surgical is a Lombard, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Relmada

Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.